Of the litany of early, shameful lessons marked on the map of the soul, there are few as damning and intense as early crushes. Immense feelings that emerge from unknown corners of the heart to steer ...

Thinking of the screen as skin means rethinking the relationship between body and technology. In Emanuela Moretti’s ...

The Weekly Notable Startup Funding Report takes us on a trip across various ecosystems in the US, highlighting some of the notable funding activity in the various markets that we track. The notable ...

Just when investors were thinking they understood the AI Boom, the rules shifted again… Forget everything you thought you knew about the “Magnificent 7.” We’ve moved beyond the individual gladiators ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The funding discussions highlight ongoing investor demand for new and unproven research labs looking to find novel approaches to AI that push the technology forward. Recursive’s goal is to develop ...

What works in controlled agentic AI demos often breaks down at scale, where integration, reliability, security, governance and performance expectations are far higher.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, JPMorgan upgraded Recursion Pharmaceuticals (NASDAQ:RXRX) to an Overweight ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...